Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Green algae, particularly species such as Chlorella and Spirulina (though the latter is technically a cyanobacterium, it is commonly grouped with green algae in supplements), have been studied for their potential impact on blood pressure. Several small-scale clinical trials and animal studies suggest a modest antihypertensive effect. For example, a randomized, double-blind, placebo-controlled trial published in Clinical and Experimental Hypertension (2009) showed that daily supplementation with Chlorella tablets led to a significant reduction in blood pressure among mildly hypertensive subjects over 12 weeks. Meta-analyses, such as one published in Clinical Nutrition (2020), have found that Spirulina supplementation may result in a small but statistically significant reduction in both systolic and diastolic blood pressure.

The proposed mechanisms include increased nitric oxide production, antioxidant effects, and improvement of lipid profiles. Despite these findings, the overall quality and quantity of evidence remain limited: studies often have small sample sizes, short durations, and sometimes lack rigorous controls. There is not yet enough high-quality evidence to recommend green algae as a primary treatment for hypertension, but current research does provide some scientific validation for its adjunctive use. Thus, the evidence supporting green algae for hypertension can be considered modest (rated 2/5).

More about green algae (unspecified)
More about Hypertension

Other ingredients used for Hypertension

Other health conditions supported by green algae (unspecified)

Products containing green algae (unspecified)